Laurus Labs announced robust performance for the first quarter of FY27, with revenue surging 29% year-on-year to ₹2,026 crore. EBITDA also saw a substantial increase of 66% to ₹644 crore, with margins expanding by 700 bps to 31.8%. Net profit grew by an impressive 126% to ₹368 crore. The company highlighted continued investment in manufacturing network expansion and niche capabilities, with CAPEX at 19% of sales.
Laurus Labs Reports Strong Q1 FY27 Performance
Laurus Labs has commenced the fiscal year 2027 with a strong financial performance, reporting a significant 29% increase in revenue to ₹2,026 crore for the first quarter (1Q FY27). This growth was primarily driven by robust CDMO revenue from commercial projects and steady momentum in the Affordable Medicines segment.
Key Financial Highlights
EBITDA and Profitability Surge
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) reached ₹644 crore, marking a substantial 66% year-on-year increase. EBITDA margins improved by 700 basis points to 31.8%, attributed to enhanced CDMO revenue and operational leverage. Net profit saw a remarkable surge of 126%, climbing to ₹368 crore.
Gross Margins Expansion
Gross margins expanded by over 3.3% to 62.7%, reflecting a healthy business segment mix. The company also reported that R&D spends were at ₹118 crore, a 74% increase driven by development efforts in its Advanced Biologics infrastructure.
Strategic Investments and Outlook
Laurus Labs continues its strategic investment in expanding its manufacturing network and niche capabilities. Overall capital expenditure (CAPEX) for the quarter stood at 19% of sales. The company’s strong Q1 performance sets a positive tone for the remainder of FY27, with particular strength noted in the CDMO and Affordable Medicines divisions.
1Q FY27 Financial Summary
| [Crore] | 4Q FY26 | 1Q FY27 | 1Q FY26 | Y-o-Y | Q-o-Q |
| Revenue | 1,812 | 2,026 | 1,570 | 29% | 12% |
| Gross Margins | 61.4% | 62.7% | 59.4% | +3.3% | +1.3% |
| EBITDA | 523 | 644 | 389 | 66% | 23% |
| % to Revenue | 28.9% | 31.8% | 24.8% | +7.0% | +2.9% |
| Net Profit | 279 | 368 | 163 | +126% | +32% |
| % to Revenue | 15.4% | 18.2% | 10.4% | +7.8% | +2.8% |
| EPS () | 5.2 | 6.8 | 3.0 | +127% | +31% |
Source: BSE
